Chapter 36. Chronic Lymphocytic Leukemia

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Bruce D. Cheson MD

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch36

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Cheson, B. D. (2008) Chronic Lymphocytic Leukemia, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch36

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Division of Hematology/Oncology, Georgetown University Hospital, Washington, DC, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • chronic lymphocytic leukemia (CLL);
  • literature-search strategy and inclusions;
  • diagnosis of CLL;
  • clinical relevance of newly identified prognostic factors;
  • optimal approach to initial treatment of patients with CLL;
  • fludarabine-based therapy as standard initial treatment of CLL;
  • management of patients with relapsed or refractory disease;
  • stem cell transplantation

Summary

This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and inclusions

  • How is the diagnosis of CLL made?

  • What is the clinical relevance of newly identified prognostic factors?

  • What is the optimal approach to the initial treatment of patients with CLL?

  • How should patients with relapsed or refractory disease be managed?

  • References